QNRX · ISSUER CIK 1671502
Quoin Pharmaceuticals, Ltd.
Between Aug 1, 2026 and Oct 29, 2026, 5 Quoin Pharmaceuticals, Ltd. insiders reported $280K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Carter Denise P. (Chief Operating Officer, Director), with $100K.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$280KInsider buying
$0.00Insider selling
+$280KNet open-market
Sep 1, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 202621:40 | Aug 31, 2026 | QNRX | Chief Operating Officer, Director | P · Buy | $4.88 | +20,490 | 37,709 | +119% | +$100K | -20.3% | -15.0% |
| Sep 1, 202621:39 | Aug 31, 2026 | QNRX | Chief Executive Officer, Director | P · Buy | $4.88 | +20,490 | 37,713 | +119% | +$100K | -20.3% | -15.0% |
| Sep 1, 202621:39 | Aug 31, 2026 | QNRX | Chief Financial Officer | P · Buy | $4.88 | +10,244 | 10,684 | +2328% | +$50K | -20.3% | -15.0% |
| Sep 1, 202621:38 | Aug 31, 2026 | QNRX | Director | P · Buy | $4.88 | +6,146 | 40,364 | +18% | +$30K | -20.3% | -15.0% |
| Aug 28, 202618:40 | Aug 27, 2026 | QNRX | Director | A · Grant | $5.15 | +34,534 | 56,243 | +159% | $178K | ||
| Aug 28, 202618:39 | Aug 27, 2026 | QNRX | Director | A · Grant | $5.15 | +31,352 | 34,218 | +1094% | $161K |